FDA Generic Director Post Is Officially Open; Uhl May Be Only Candidate
This article was originally published in The Pink Sheet Daily
FDA is taking applications to head up the Office of Generic Drugs; the question is whether anyone wants the “pressure cooker” job.
You may also be interested in...
FDA Generics Office Gets Third Director In Three Workdays; Uhl Brings Policy, Pharmacology Experience
A long-time FDA veteran who remains largely unknown to the generics industry, Kathleen Uhl replaces CDER Director Janet Woodcock as acting director of the Office of Generic Drugs effective March 19 following Gregory Geba’s March 15 departure from the generic office’s top post.
Another outside candidate is expected to eventually take over for the departing director Gregory Geba, and while the Office of Generic Drugs can run smoothly without a permanent leader for now, it cannot do so forever.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.